The drug-eluting stent information gap

Am Heart Hosp J. 2004 Winter;2(1):21-5. doi: 10.1111/j.1541-9215.2004.03320.x.

Abstract

Drug-eluting stents are quickly replacing bare-metal stents as the arterial revascularization device of choice. Because nearly all the information we have about patient outcomes with drug-eluting stents is from trials designed for US Food and Drug Administration approval, we are missing some of the information critical to a more comprehensive understanding of how these new devices will perform at the population level.

Publication types

  • Review

MeSH terms

  • Coated Materials, Biocompatible / administration & dosage*
  • Community Health Planning / standards
  • Confounding Factors, Epidemiologic
  • Coronary Disease / therapy
  • Data Collection / standards
  • Device Approval / standards
  • Drug Information Services / standards*
  • Drug Therapy / economics
  • Drug Therapy / instrumentation*
  • Equipment Safety / standards
  • Humans
  • Materials Testing / standards
  • Myocardial Revascularization / economics
  • Myocardial Revascularization / instrumentation*
  • Needs Assessment / standards
  • Patient Selection
  • Recurrence
  • Reproducibility of Results
  • Research Design / standards
  • Stents / economics
  • Stents / standards*
  • Technology Assessment, Biomedical / standards
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Coated Materials, Biocompatible